Cogent Biosciences (COGT) Payables (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Payables of $13.7 million for Q1 2026, down 2.9% year-over-year from $14.2 million in Q1 2025, and up 44.61% quarter-over-quarter from $9.5 million in Q4 2025.
Cogent Biosciences (COGT) Payables (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Payables for 10 consecutive years, with $13.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 2.9% year-over-year to $13.7 million; the TTM figure through Mar 2026 stood at $13.7 million (down 2.9% YoY), while the FY2025 annual figure was $9.5 million, down 20.89% from the prior year.
- Payables improved to $13.7 million in Q1 2026 per COGT's latest filing, from $9.5 million in the prior quarter.
- Across five years, Payables topped out at $16.6 million in Q2 2025 and bottomed at $3.5 million in Q2 2022.
- Historically, Payables has averaged $10.1 million across 5 years, with a median of $9.9 million in 2023.
- Annual changes were most pronounced in 2022 — Payables surged 1174.6% — and 2025, when it retreated 20.89%.
- Cogent Biosciences' Payables stood at $5.8 million in 2022, then soared by 82.39% to $10.7 million in 2023, then gained by 12.75% to $12.0 million in 2024, then declined by 20.89% to $9.5 million in 2025, then soared by 44.61% to $13.7 million in 2026.
- Business Quant data shows COGT's Payables at $13.7 million in Q1 2026, $9.5 million in Q4 2025, and $16.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | 7.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.49 Mn |
| Mar 31, 2026 | 13.74 Mn |
| Dec 31, 2025 | 9.50 Mn |
| Sep 30, 2025 | 16.03 Mn |
| Jun 30, 2025 | 16.63 Mn |
| Mar 31, 2025 | 14.15 Mn |
| Dec 31, 2024 | 12.01 Mn |
| Sep 30, 2024 | 15.06 Mn |
| Jun 30, 2024 | 8.98 Mn |
| Mar 31, 2024 | 15.57 Mn |
| Dec 31, 2023 | 10.66 Mn |
| Sep 30, 2023 | 9.87 Mn |
| Jun 30, 2023 | 7.16 Mn |
| Mar 31, 2023 | 4.17 Mn |
| Dec 31, 2022 | 5.84 Mn |
| Sep 30, 2022 | 4.09 Mn |
| Jun 30, 2022 | 3.49 Mn |
| Mar 31, 2022 | 4.02 Mn |
| Dec 31, 2021 | 3.48 Mn |
| Sep 30, 2021 | 4.35 Mn |